II期黑色素瘤的辅助治疗:需要进一步研究
免疫检查点抑制剂已革新黑色素瘤治疗,高危III期术后辅助帕博利珠单抗、纳武利尤单抗或达拉非尼联合曲美替尼可显著改善无复发生存(RFS)和无远处转移生存(DMFS)。IIB/C期两项关键辅助试验亦报告RFS和DMFS显著改善,但绝对获益低,且存在严重毒性及内分泌毒性长期 morbidity 的担忧。基于分子风险分层的个体化治疗能力滞后,亟需评估组织和血液生物标志物以更好筛选复发患者、避免多数仅手术治愈者接受不必要治疗。
要点
- 高危III期术后辅助帕博利珠单抗、纳武利尤单抗或达拉非尼联合曲美替尼可显著改善RFS和DMFS。
- IIB/C期辅助帕博利珠单抗和纳武利尤单抗试验显示RFS和DMFS显著改善,但绝对获益低且有严重毒性担忧。
- 基于分子风险分层的个体化治疗能力滞后,亟需评估组织和血液生物标志物。
核心结论
- II期黑色素瘤辅助治疗绝对获益低且存在严重毒性担忧,亟需评估组织和血液生物标志物以更好筛选复发患者并避免多数仅手术治愈者接受不必要治疗。
研究设计与样本
- 本文为综述,讨论II期黑色素瘤辅助治疗相关关键试验及个体化治疗需求。
主要发现
- 转移性黑色素瘤中,纳武利尤单抗联合伊匹木单抗治疗的预期5年生存率>50%。
- 已切除高危III期患者中,辅助帕博利珠单抗、纳武利尤单抗或达拉非尼联合曲美替尼与RFS和DMFS显著改善相关。
- IIB/C期两项关键辅助试验(帕博利珠单抗和纳武利尤单抗)报告RFS和DMFS均显著改善,但绝对获益低。
- 新辅助免疫治疗在临床可检测淋巴结病变患者中显示出非常有前景的结果,可能成为新标准治疗。
- 正在进行的注册III期试验正在评估更新的免疫联合方案及BRAF/MEK靶向治疗在II期黑色素瘤中的作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- II期黑色素瘤辅助治疗的绝对获益低。
- 存在严重毒性风险及内分泌毒性导致的长期 morbidity 担忧。
- 基于分子风险分层的个体化治疗能力滞后于新型免疫治疗的发展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy with checkpoint inhibitors has revolutionised the outcomes for melanoma patients. In the metastatic setting, patients treated with nivolumab and ipilimumab have an expected 5-year survival of> 50%. For patients with resected high-risk stage III disease, adjuvant pembrolizumab, nivolumab or dabrafenib and trametinib are associated with a significant improvement in both relapse-free survival (RFS) and distant metastasis-free survival (DMFS). More recently neoadjuvant immunotherapy has shown very promising outcomes in patients with clinically detectable nodal disease and is likely to become a new standard of care. For stage IIB/C disease, two pivotal adjuvant trials of pembrolizumab and nivolumab have also reported a significant improvement in both RFS and DMFS. However, the absolute benefit is low and there are concerns about the risk of severe toxicities as well as long-term morbidity from endocrine toxicity. Ongoing registration phase III trials are currently evaluating newer immunotherapy combinations and the role of BRAF/MEK-directed targeted therapy for stage II melanoma. However, our ability to personalise therapy based on molecular risk stratification has lagged behind the development of novel immune therapies. There is a critical need to evaluate the use of tissue and blood-based biomarkers, to better select patients that will recur and avoid unnecessary treatment for the majority of patients cured by surgery alone.
引用
- Lee R, Mandala M, Long GV, et al. Adjuvant therapy for stage II melanoma: the need for further studies. Eur J Cancer. 2023. PMID: 37301717. doi:10.1016/j.ejca.2023.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。